Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers

Oncogene

Volumn 27, Issue 33, 2008, Pages 4569-4579

  Zhu, Q ^a,b   Youn, H ^b   Tang, J ^b   Tawfik, O ^b   Dennis, K ^b   Terranova, P F ^c   Du, J ^d   Raynal, P ^e   Thrasher, J B ^b   Li, B ^a,b,c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e CHU PURPAN   (France)

Author keywords

Androgen receptor; Mouse xenograft; PI3K; Prostate cancer; siRNA; Tumor progression

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P110BETA; PHOSPHATIDYLINOSITOL 3 KINASE P85ALPHA; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER TISSUE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA INTERACTION; PROTEIN FUNCTION; RNA INTERFERENCE; TRANSACTIVATION; WILD TYPE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGENS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS);

MUS MUSCULUS;

EID: 48649083369     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.91     Document Type: Article

References (33)

1. Bader AG, Kang S, Zhao L, Vogt PK. (2005). Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929.
2. Chini B, Parenti M. (2004). G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there? J Mol Endocrinol 32: 325-338.
3. Cinar B, Mukhopadhyay NK, Meng G, Freeman MR. (2007). Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem 282: 29584-29593.
4. Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G et al. (2003). Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 31: e127.
5. Engelman JA, Luo J, Cantley LC. (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
6. Hayakawa M, Kaizawa H, Moritomo H, Koizumi T, Ohishi T, Okada M et al. (2006). Synthesis and biological evaluation of 4-morpholino-2- phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem 14: 6847-6858.
7. Heinlein CA, Chang C. (2004). Androgen receptor in prostate cancer. Endocr Rev 25: 276-308.
8. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L et al. (2004). Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164: 217-227.
9. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE et al. (2005). PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11: 507-514.
10. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P et al. (2005). Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem 280: 11583-11589.
11. Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O et al. (2001). Evaluation of androgen, estrogen (ERalpha and ERbeta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919-1926.
12. Lee SO, Lou W, Hou M, Onate SA, Gao AC. (2003). Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene 22: 7981-7988.
13. Li B, Liao XB, Fujito A, Thrasher JB, Shen FY, Xu PY. (2007a). Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells. Asian J Androl 9: 41-50.
14. Li B, Sun A, Youn H, Hong Y, Terranova PF, Thrasher JB et al. (2007b). Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 28: 572-583.
15. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
16. Li P, Nicosia SV, Bai W. (2001). Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem 276: 20444-20450.
17. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. (2005). Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4: 505-515.
18. Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B. (2004). Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology 145: 2941-2949.
19. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. (2001). Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 276: 13442-13451.
20. Majumder PK, Sellers WR. (2005). Akt-regulated pathways in prostate cancer. Oncogene 24: 7465-7474.
21. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. (2004). HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527.
22. Murga C, Laguinge L, Wetzker R, Cuadrado A, Gutkind JS. (1998). Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinasegamma. J Biol Chem 273: 19080-19085.
23. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. (2001). Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142: 4795-4805.
24. Scher HI, Sawyers CL. (2005). Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261.
25. Shang Y, Myers M, Brown M. (2002). Formation of the androgen receptor transcription complex. Mol Cell 9: 601-610.
26. Shanmugam I, Cheng G, Terranova PF, Thrasher JB, Thomas CP, Li B. (2007). Serum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival. Cell Death Differ 14: 2085-2094.
27. Sharma M, Chuang WW, Sun Z. (2002). Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J Biol Chem 277: 30935-30941.
28. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
29. Sun A, Shanmugam I, Song J, Terranova PF, Thrasher JB, Li B. (2007a). Lithium suppresses cell proliferation by interrupting E2F-DNA interaction and subsequently reducing S-phase gene expression in prostate cancer. Prostate 67: 976-988.
30. Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S, Li C et al. (2007b). Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 67: 203-213.
31. Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R et al. (2003). Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem 278: 42992-43000.
32. Yart A, Roche S, Wetzker R, Laffargue M, Tonks N, Mayeux P et al. (2002). A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem 277: 21167-21178.
33. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. (2005). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 102: 18443-18448.